Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWILOID vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension (mild to moderate),Psychiatric disorders (e.g., schizophrenia, anxiety) – historically used
Hypertension
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via cytochrome P450 enzymes (CYP2D6 and CYP3A4); undergoes extensive first-pass metabolism.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 90% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Approximately 1.6 L/kg. Clinical meaning: Indicates extensive tissue distribution beyond plasma volume; consistent with peripheral binding and accumulation in tissues.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: Approximately 30–50% due to first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Not recommended in patients with GFR <30 m L/min; for GFR 30-60 m L/min, reduce dose by 50%.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use is contraindicated.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at 1 mg orally once daily; increase slowly with close monitoring of blood pressure.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause depression (including suicidal ideation), bradycardia, orthostatic hypotension, nasal congestion, and gastrointestinal disturbances. Use with caution in patients with history of depression, peptic ulcer disease, or colitis. Avoid abrupt discontinuation to prevent rebound hypertension.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to rauwolfia alkaloids, history of depression (especially with suicidal tendencies), active peptic ulcer disease, ulcerative colitis, pheochromocytoma, and concurrent use with MAO inhibitors.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) as Rauwiloid may potentiate pressor effects; limit sodium intake to enhance antihypertensive effect; avoid large amounts of caffeine.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trimesters: may cause fetal bradycardia, hypotension, and hypothermia if used near term. Avoid use in pregnancy unless clearly needed.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Not known whether alseroxylon is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug. M/P ratio not available.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect drug levels; however, due to limited data, dose should be individualized and titrated to clinical response.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid used for mild to moderate hypertension; its antihypertensive effect is due to depletion of catecholamines from peripheral sympathetic nerve endings; onset is slow (weeks) and prolonged; common side effects include nasal congestion, bradycardia, and depression; avoid in patients with history of depression or peptic ulcer disease; may cause sodium and water retention; taper dose to avoid rebound hypertension.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed; do not stop suddenly as this may cause a rapid increase in blood pressure.,Avoid alcohol and other central nervous system depressants as they can worsen drowsiness or dizziness.,You may experience nasal congestion, dry mouth, or slowed heart rate; report any signs of depression or mood changes.,Rise slowly from sitting or lying positions to prevent dizziness or fainting.,This medication may take several weeks to achieve full effect; continue taking it even if you feel well.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWILOID vs ALDORIL D30, answered by our medical review team.
RAUWILOID is a Antihypertensive that works by Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWILOID and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWILOID is: 2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWILOID and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWILOID is classified as Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trim. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.